Cart
sales@molnova.com
PRN371
CAS No. 1610974-55-4
PRN371( PRN 371 )
Catalog No. M12331 CAS No. 1610974-55-4
PRN371 is a novel potent, selective JAK3 inhibitor with IC50 of 0.5 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePRN371
-
NoteResearch use only, not for human use.
-
Brief DescriptionPRN371 is a novel potent, selective JAK3 inhibitor with IC50 of 0.5 nM.
-
DescriptionPRN371 is a novel potent, selective JAK3 inhibitor with IC50 of 0.5 nM, displays >250-fold selectivity over JAK1, JAK2, and TYK2; effectively inhibits IL-2 induces JAK1/3-STAT5 phosphorylation in PBMCs with IC50 of 99 nM, effectively blocks JAK3-mediated signaling in JAK3-driven cancer cells; effectively inhibits the growth of NKTL cells via suppressing the JAK3-STAT pathway, and exhibits a more durable inhibition on JAK3 compared to tofacitinib in vitro; significantly inhibits tumor growth in NKTL xenograft model harboring JAK3 activating mutation.
-
In Vitro——
-
In Vivo——
-
SynonymsPRN 371
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610974-55-4
-
Formula Weight363.421
-
Molecular FormulaC20H21N5O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name2-(3-acrylamidophenyl)-N-(tert-butyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
BT-11
BT-11 is an orally available LANCL2 binding compound. It is used in the therapy of inflammatory bowel disease.
-
PF-06651600
PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical
-
Axltide
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).Peptide sequence (KKSRGDYMTMQIG) is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).
